The Asia Pacific point of care diagnostics market is expected to reach USD 15.61 billion by 2030, registering a CAGR of 8.1%, according to a new study by Grand View Research, Inc. Growing base of geriatric population and the ability to render immediate results and improve patient care coupled with a rising market penetration of PACS (picture archiving and communication systems) and EMR (electronic medical records) are expected to drive demand over the next six years. Skilled staff shortages, especially pertaining to the field of diagnostics are also expected to accelerate the market penetration rates of point of care (PoC) products, by expediting lab automation processes. Rising demand for home healthcare and other healthcare establishments catering to the elderly population and initiatives undertaken by governments to shorten hospital stays by establishing out-patient care models are also expected to be key market factors.
The rapidly growing use of point of care diagnostic products has introduced a decentralization trend in the overall healthcare industry. Healthcare facilities and patients, in an attempt to attain or cater medical facilities remotely, encourage early diagnosis and curb costs are now decentralizing their facilities. Furthermore, these trends have also triggered the establishment of remote and stand-alone diagnostic facilities.
Request a free sample copy or view report summary: Asia Pacific Point Of Care Diagnostics Market Report
The infectious diseases segment dominated the market with the highest revenue share in 2022 owing to the increasing adoption of point of care diagnostics as a substitute for traditional laboratory testing in infectious diseases applications.
The cancer markers segment is expected to grow at the fastest CAGR over the forecast period from 2023 to 2030. The Asia Pacific region has experienced a notable rise in the prevalence of cancer in recent years.
The clinics segment held the largest revenue share of over 35% in 2022. Clinics are essential in providing healthcare services, particularly in remote and underserved areas.
China dominated the Asia Pacific PoC diagnostics market with a revenue share of over 40% in 2022. China has the world's largest population and faces notable challenges related to the prevalence of chronic and infectious diseases within its borders resulting in an increasing demand for point-of-care diagnostics.
Grand View Research has segmented the Asia Pacific point of care diagnostics market report on the basis of product, end-use, and region:
Asia Pacific Point Of Care Diagnostics Product Outlook (Revenue, USD Million, 2018 - 2030)
Glucose Testing
Hb1Ac Testing
Coagulation
Fertility/Pregnancy
Infectious Disease
HIV POC
Clostridium Difficile POC
HBV POC
Pneumonia or Streptococcus Associated Infections
Respiratory Syncytial Virus (RSV) POC
HPV POC
Influenza/Flu POC
HCV POC
MRSA POC
TB and Drug-resistant TB POC
HSV POC
COVID-19
Other Infectious Diseases
Cardiac Markers
Thyroid Stimulating Hormone
Hematology
Primary Care Systems
Decentralized Clinical Chemistry
Feces
Lipid Testing
Cancer Marker
Blood Gas/Electrolytes
Ambulatory Chemistry
Drug Abuse Testing
Autoimmune Disease
Urinalysis/Nephrology
Asia Pacific Point Of Care Diagnostics End-use Outlook (Revenue, USD Million, 2018 - 2030)
Clinics
Physician Office
Pharmacy & Retail Clinics
Non-practice Clinics
Urgent Care Clinic
Hospitals
Home
Assisted Living Healthcare Facilities
Laboratory
Asia Pacific Point Of Care Diagnostics Regional Outlook (Revenue, USD Million, 2018 - 2030)
Asia Pacific
China
Japan
India
South Korea
Australia
Thailand
New Zealand
Singapore
Vietnam
List of Key Players in the Asia Pacific Point Of Care Diagnostics Market
Wipro
ZOE Limited
Vocalis Health
DarwinAI
Biocogniv Inc.
Laipac Technology Inc.
Gauss Surgical, Inc.
Oxford Immune Algorithmics Ltd
F. Hoffmann-La Roche Ltd.
QIAGEN
Danaher
Beckman Coulter, Inc.
Radiometer Medical ApS
HemoCue AB
BD (Becton, Dickinson, and Company)
BIOMÉRIEUX
Abbott
Siemens Healthcare GmbH
Zoetis Services LLC
Abaxis
Instrumentation Laboratory Company
Nova Biomedical
Trividia Health, Inc.
Quidel Corporation
Trinity Biotech
SEKISUI Diagnostics
Orasure Technologies, Inc.
Nipro Europe Group Companies
Spectral Medical Inc.
"The quality of research they have done for us has been excellent..."